The article mentions that 4D Molecular Therapeutics has received 5 bullish and 1 indifferent analyst ratings in the last quarter. The average price target has increased by 50.81% from the previous target, indicating a potential upside for the stock. This positive sentiment from analysts is likely to have a short-term positive impact on the stock price.